Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1261-1280 of 3,900 trials

Self-Administration of Elranatamab for Multiple Myeloma

We are exploring whether patients with multiple myeloma can safely administer Elranatamab at home. The study will assess the feasibility, safety, and impact on quality of life for both patients and their caregivers.

Multiple Myeloma1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Acute Myeloid Leukemia: Gilteritinib with Venetoclax and Azacitidine

We are studying a combination of three medications for patients with newly diagnosed acute myeloid leukemia and FLT3 mutations who cannot receive intensive treatment. The goal is to find the best dose that is safe and effective.

Acute Myeloid LeukemiaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Mpox Vaccination Study: MPOX-VAX

We are studying a vaccine to see how well it prevents Mpox infection and how long the immune response lasts. Participants will also be monitored for other infections to understand overall health impacts.

Mpox Infection6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Systemic Juvenile Idiopathic Arthritis: Baricitinib Study

We are studying the effectiveness of baricitinib in children aged 1 to under 18 with systemic juvenile idiopathic arthritis. This research aims to find out if it helps improve their condition.

Systemic Juvenile Idiopathic Arthritis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Advanced Cancer: Targeted Drug Study

We are investigating whether approved cancer drugs can help patients with advanced cancer who have specific genetic markers. This study aims to improve treatment options by using these drugs in new ways.

CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Esophageal Strictures: Budesonide Tablets

We are studying whether budesonide tablets can help prevent esophageal strictures in adults after cancer surgery. This trial compares two doses of the medication to a placebo to assess effectiveness and safety.

Oesophageal Cancer and Related Conditions>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesGastroenterologyOncology

Isatuximab for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

We are studying whether Isatuximab can safely help adults with relapsed or refractory T-cell acute lymphoblastic leukemia achieve remission. This trial looks at its effects alone and with other chemotherapy drugs.

T-cell Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Etentamig Injection Study

We are investigating the safety and effectiveness of a new injectable treatment for patients with relapsed or refractory Multiple Myeloma. This study aims to understand how well it works compared to existing therapies.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)Oncology

Ovarian Cancer: Raludotatug Deruxtecan Study

We are studying a new drug for patients with platinum-resistant, high-grade ovarian cancer. The goal is to see if it works better than current treatment options.

Ovarian and Related Cancers>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Scabies Treatment: Comparing Permethrin Creams

We are testing whether a new 10% permethrin cream works better than the standard 5% cream for treating scabies. We will also look at the safety of the new cream.

Scabies>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyInfectious Diseases

Methylphenidate for Cancer-Related Fatigue in Young Brain Tumor Survivors

We are studying whether methylphenidate can help reduce fatigue in patients who were treated for brain tumors during childhood or adolescence. Additionally, we will look at its effects on sleep, cognitive function, and quality of life.

Cancer-related Fatigue after Pediatric Brain Tumor Treatment3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementOncologyPediatrics

Quizartinib for Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

We are studying whether quizartinib, combined with chemotherapy, can improve survival in adults with newly diagnosed FLT3-ITD negative AML compared to a placebo. This trial aims to assess its effectiveness and safety.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementOncology

Advanced Solid Tumors: First-in-Human Study of DS-3939a

We are testing a new treatment called DS-3939a to see if it is safe and effective for people with advanced solid tumors. This study aims to understand how well it works and its effects on tumor tissue.

Metastatic Solid TumorAdvanced Solid TumorSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Biliary Tract Cancers: [18F]F-FAPI PET-CT Imaging Study

We are investigating how a new imaging technique may improve diagnosis and treatment planning for patients with potentially resectable biliary tract cancers. This study will also look at the cost-effectiveness and safety of this imaging method.

Cholangiocarcinoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Colchicine for Angina in Microvascular Disease

We are studying whether colchicine can improve blood flow and reduce symptoms in patients with angina caused by coronary microvascular dysfunction. This research may help us understand how to better treat this condition.

Cardiovascular Disease (CMD)>2 yearsEfficacy phase (II)Standard MedicinesCardiology

Pompe Disease: Enzyme Replacement Therapy Study

We are examining how a new enzyme replacement therapy affects muscle glycogen in people with Pompe disease who have not yet received treatment. This research may help improve future therapies for this condition.

Pompe's Disease>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyHematologyNeurology

DZR123 for Advanced Solid Tumors and Lymphomas

We are studying a new treatment called DZR123 for patients with advanced solid tumors and lymphomas. The trial will help us understand its safety and how well it works alone and with another medication.

Advanced Solid Tumors and Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Chronic Lymphocytic Leukemia: Lisaftoclax Treatment Study

We are studying whether a new drug, lisaftoclax, combined with another treatment, helps patients with chronic lymphocytic leukemia who have been previously treated. The goal is to see if this combination improves survival and slows disease progression.

Chronic Lymphocytic Leukemia (CLL) / Small Cell Lymphocytic Lymphoma (SLL)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Ovarian Cancer: Sacituzumab Tirumotecan Study

We are testing a new treatment for people with recurrent ovarian cancer to see if it works better than standard care. This study looks at safety, tolerability, and how it affects patients' quality of life.

Recurrent Ovarian CancerConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementOncology

Levosimendan for Heart Support During ECMO Weaning

We are studying whether Levosimendan can improve heart function in patients being weaned from ECMO. This may help reduce complications and support recovery during this critical period.

Cardiogenic ShockEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine